About us
Learn more about Imperagen and meet our team
Established in 2021, Imperagen is a pioneering Techbio company, focused on accelerating the process of enzyme engineering. Serving diverse markets, from pharmaceutical manufacturing and life sciences to sustainable fine chemical production and industrial applications, we work hand-in-hand with our customers to de-risk and streamline their product development and fast track their path to market.
At the heart of our approach is our Digital Enzyme EvolutionTM technology – a fully integrated, digitialized platform that revolutionizes enzyme development. By unifying AI-led protein design with novel biotechnology and laboratory automation, it enables the creation of high-performance enzymes with unprecedented speed, accuracy and reliability.
Our leadership team brings over 100 years of combined experience in biotech R&D and commercialisation, with a highly talented research team that spans synthetic biology, chemistry, and computational science. We operate out of our state-of-the-art facilities in Manchester, UK — home to the Manchester Institute of Biotechnology and the Alan Turing Institute —the world’s original industrial city and now a thriving global-hub for biotechnology and digital innovation.
We’re proud to be backed by visionary UK-based investors IQ Capital and Northern Gritstone, who share our commitment to leveraging digitalization to transform biotechnology and help our customers deliver truly transformative products.
Meet our team
Management Team / Executive Board Members
Rob Wilson
Chief Executive Officer
Rob is an experienced executive with an international background in pharmaceuticals, life sciences and enzyme technology, having held business leadership roles at Avecia, Codexis and DNA Script in the UK, US and Singapore.
Andrew Currin
Chief Scientific Officer – Co-founder
Andrew is a leading expert in the fields of directed evolution, enzymology and synthetic biology and the architect of the patented gene assembly technologies underpinning Imperagen’s automated enzyme engineering platform.
Andrew Almond
Chief Information Officer – Co-founder
Andrew is a leading biophysicist and an experienced entrepreneur, having co-founded and helped to IPO C4X Discovery in 2014, before leading the spin-out of Imperagen in 2021. He is the driving force behind Imperagen’s patented approach to AI-led design and optimisation of enzymes.
Tim Eyes
Chief Product Officer – Co-founder
Tim is an experienced protein engineer with academic and Big Pharma experience spanning both enzyme and antibody technologies. He leads product development and commercial engagement for Imperagen.
Non-Executive Board Members
Peter Seufer-Wasserthal
Non-Executive Chairman
Peter brings over 30 years of industrial biotechnology and life sciences commercialisation experience, supporting biotechnology companies’ development and profitability.
Jessica McCreadie
Investor-representative Board Member
Jess is an Investment Director at Northern Gritstone. Prior to Northern Gritstone, Jess held roles as a Principal at Octopus Ventures specialising in Health Tech and B2B SaaS and as an Investment Director at L&G, investing in Health Tech, Clean Tech and Infrastructure scale Clean Energy. Jess has a First Class BA (Hons) in International Business from the University of Strathclyde.
Alex Wilson
Investor-representative Board Member
Alex is a Partner at IQ Capital. He is interested in working with founder teams who are deeply committed to advancing society by solving complex problems rooted in biology. Prior to joining IQ Capital, Alex completed a PhD in Computational Biology at the University of Manchester where he studied applications of ML in protein simulation, leading to five publications.
Advisory Board
John Woodley
Advisor, Biocatalysis
John is currently Professor of Chemical Engineering at Technical University of Denmark. He has published over 300 papers with over 30 years’ experience in the scale-up and scale-down of biocatalytic processes.
Frank Craig
Advisor, Platform Technology and Automation
Frank was a co-founder and a VP of Aurora Biosciences (San Diego, USA) and has also worked for GSK and GE Healthcare in senior scientific roles. Frank has raised over £250m in investment and commercial partnerships.
Mark Dearden
Advisor, Life Sciences
Mark is an experienced life sciences executive with over 30 years of global life sciences experience. He has a strong focus on growth and scale-up, leading innovation and commercial strategy across the pharmaceutical, diagnostics, and applied research sectors.